Tesofensine

Tesofensine is a novel triple monoamine reuptake inhibitor developed for the treatment of obesity. It functions by inhibiting the reuptake of three key neurotransmitters—serotonin, norepinephrine, and dopamine—thereby increasing their levels in the brain. This action leads to appetite suppression and potential increases in energy expenditure, contributing to weight loss.

How Does Tesofensine Work?

Development and Mechanism

Tesofensine was originally developed to treat Parkinson’s disease by increasing dopamine levels. However, during clinical trials, a notable side effect—significant weight loss—was observed. Since the drug was less effective for Parkinson’s compared to existing treatments but nearly twice as effective for weight loss, research shifted focus to obesity treatment.

Tesofensine is a triple neurotransmitter reuptake inhibitor, affecting dopamine, norepinephrine, and serotonin levels. However, it is more potent at increasing norepinephrine and serotonin than dopamine, which may explain its limited success in Parkinson’s treatment.

Besides these, tesofensine indirectly enhances cholinergic neurotransmission, promoting cognition, learning, and memory by increasing brain-derived neurotrophic factor (BDNF) levels—a protein associated with neuron growth and benefits in depression, cognitive decline, and other neurological conditions.

Tesofensine and Weight Loss

Phase IIB clinical trials show tesofensine produces approximately 12.8 kg (28 lbs) of weight loss over 6 months on a 1 mg dose combined with a 300 kcal/day deficit. This is roughly six times the weight loss compared to placebo and twice as effective as FDA-approved weight-loss drugs.

The drug is orally administered once daily with a favorable side effect profile, mostly dry mouth, headache, gastrointestinal upset, and sleep difficulty—these effects are dose-dependent and tend to diminish with long-term use.

Tesofensine works best alongside calorie restriction and exercise but still produces weight loss even without lifestyle changes. It increases satiety and energy expenditure during sleep and enhances fat oxidation.

Satiety and Appetite Regulation

Tesofensine significantly reduces hunger sensations and appetite, but these effects revert soon after stopping the drug. Appetite control seems deeply ingrained and difficult to modify permanently; tesofensine helps temporarily suppress persistent hunger signals, aiding weight loss.

Its appetite-suppressing effects diminish with prolonged use but rebound after short breaks, suggesting cycling the drug could enhance long-term outcomes.

Tesofensine and Blood Sugar

In rats, tesofensine improves glycemic control by attenuating insulin responses to glucose loads, lowering insulin release. Since insulin promotes fat storage, this helps reduce fat accumulation. It may also disrupt the self-reinforcing cycle of fat accumulation and inflammation linked to insulin resistance, diabetes, heart disease, and neurodegeneration.

Tesofensine and Brain Health

Although abandoned for Parkinson’s treatment, tesofensine boosts BDNF expression and neurogenesis in the hippocampus, supporting cognition, memory, and cell survival. BDNF dysregulation is involved in depression, schizophrenia, Alzheimer’s, and other disorders, making tesofensine a candidate for broader neurological benefits.

Tesofensine and Depression

Stress reduces BDNF and causes hippocampal atrophy linked to depression. Tesofensine increases BDNF and neurogenesis, suggesting antidepressant potential. Its dual effect on weight loss and mood may help people managing both obesity and depression.

Tesofensine and Pain Management

Traditional antidepressants modulate pain perception; dopamine enhancement further improves anti-pain effects. Tesofensine’s triple reuptake inhibition may provide novel benefits in pain management.

Safety Profile

Unlike many anti-obesity drugs with serious cardiac side effects (e.g., Fen-Phen, sibutramine), tesofensine has a better cardiovascular risk profile due to central neurotransmitter action rather than peripheral mechanisms. Some concerns about trial design and side effect reporting exist, but overall tesofensine’s side effects are minimal and manageable.

Summary

Tesofensine is a potent inhibitor of serotonin, norepinephrine, and dopamine reuptake, increasing BDNF and neurogenesis. It is currently the most effective weight loss compound in clinical trials, with promising neurocognitive and mood-related benefits. Ongoing research continues to explore its full therapeutic potential.

Research Applications

Tesofensine is primarily utilized in scientific studies focusing on:

• Appetite Suppression: Investigating its role in reducing food intake by modulating neurotransmitter levels.
• Weight Loss: Assessing its efficacy in promoting weight loss in obese individuals.
• Metabolic Effects: Exploring its impact on energy expenditure and fat oxidation.
• Neurocognitive Effects: Studying its potential effects on cognition and mood.

Product Specifications

• Form: Lyophilized (freeze-dried) powder encapsulated in capsules.
• Dosage: Each capsule contains 500mcg of Tesofensine.
• Quantity: Typically available in bottles containing 30 capsules.
• Purity: ≥99%, ensuring high-quality material for research purposes.
• Packaging: Sealed bottles to maintain product integrity.
• Storage: Store in a cool, dry place away from direct sunlight.

Safety and Handling

Tesofensine is intended strictly for laboratory research and is not approved for human consumption. Handle with care, following appropriate safety protocols. Ensure proper storage conditions to maintain the integrity and efficacy of the compound.

Referenced Citations

• Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010 Jul;88(1):69-78. doi:10.1038/clpt.2010.67. 
• Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008 Jun;16(6):1363-9. doi:10.1038/oby.2008.56. 
• Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol. 2007 Jan;555(2-3):115-21. doi:10.1016/j.ejphar.2006.10.029. 
• Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep;372(9653):1906-13. doi:10.1016/S0140-6736(08)61525-1. 
• Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial. GlobeNewswire News Room, Dec. 17, 2018. 
• Sjodin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010 Nov;34(11):1634-43. doi:10.1038/ijo.2010.87. 
• Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012 Mar;20(3):553-61. doi:10.1038/oby.2011.197. 
• Axel MD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha2-adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010 Jul;35(7):1464-76. doi:10.1038/npp.2010.16. 
• Hansen HH, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 10;636(1-3):88-95. doi:10.1016/j.ejphar.2010.03.026. 
• Drzyzga RD, Marcinowska A, Obuchowicz E. Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res Bull. 2009 Jun;79(5):248-57. doi:10.1016/j.brainresbull.2009.03.009. 
• Korte SM, et al. The many different faces of major depression—it is time for personalized medicine. Eur J Pharmacol. 2015 Apr 5;753:88-104. doi:10.1016/j.ejphar.2014.11.045. 
• Marks DM, Pae CU, Patkar AA. Triple Reuptake Inhibitors: The Next Generation of Antidepressants. Curr Neuropharmacol. 2008 Dec;6(4):338-43. doi:10.2174/157015908787386078. 
• Cheung BMY, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi:10.1177/2042098613489721. 
• George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi:10.1177/1074248413501017. 
• Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Under-reporting of adverse effects of tesofensine. Lancet. 2013 Jul 20;382(9887):127. doi:10.1016/S0140-6736(13)61563-9.